Amplia Therapeutics publishes narmafotinib pancreatic cancer preprint

A Garvan Institute preprint shows Amplia's FAK inhibitor reduced tumour fibrosis, chemotherapy resistance and metastatic spread in preclinical pancreatic cancer models.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A scientific instrument is positioned above a clear tray containing multiple translucent spheres lit by internal red and green lights in a brightly lit laboratory setting.

Amplia Therapeutics has announced the online publication of a scientific manuscript on its lead asset narmafotinib, posted to the bioRxiv preprint server on 31 July 2026. The paper was authored by Professor Paul Timpson and colleagues at the Garvan Institute of Medical Research in Sydney, and represents what Amplia describes as one of the most comprehensive preclinical evaluations of the compound to date.

The manuscript reports four headline findings. First, narmafotinib reduced tumour fibrosis, a defining feature of pancreatic cancer that limits drug penetration and contributes to poor outcomes. Second, the compound showed enhanced anti-tumour activity when combined with chemotherapy across multiple preclinical models. Third, it reduced cancer dissemination in a metastatic model. Fourth, the drug downregulated a suite of genes associated with chemotherapy resistance, which the company says strengthens the biological case for combination regimens.

Clinical context

Narmafotinib is a selective inhibitor of Focal Adhesion Kinase (FAK), a signalling protein that is over-expressed in pancreatic cancer and plays a role in fibrosis, tumour stiffness and immune exclusion. The compound is already in clinical development. Amplia's ACCENT trial, which combines narmafotinib with gemcitabine and Abraxane in first-line advanced pancreatic cancer, has reported a response rate of 36% and a median overall survival of 11.1 months. A second Australian study, AMPLICITY, is examining the drug alongside FOLFIRINOX, and a third trial, PRROSE, in ovarian cancer is set to open shortly.

Chief executive Chris Burns said the Garvan Institute's work "strengthens the scientific rationale for the clinical development of narmafotinib" and offers further insight into "the multifaceted mechanisms through which narmafotinib can act." The manuscript is a preprint and has not yet completed peer review, a caveat Amplia does not flag in its announcement.

Market landscape

Pancreatic ductal adenocarcinoma remains one of oncology's most intractable targets. Five-year survival rates sit below 15% for all-stage disease, and the standard gemcitabine-plus-Abraxane doublet has changed little since its adoption roughly a decade ago. The FOLFIRINOX regimen offers marginally better outcomes in fit patients but carries a heavier toxicity burden. FAK inhibition has attracted growing industry attention as a strategy to address the tumour microenvironment rather than cancer cell proliferation alone; a number of academic and industry groups are pursuing FAK-directed approaches or combination strategies targeting tumour stroma.

Amplia is an ASX-listed company of modest market capitalisation, and the preprint publication is a relatively low-cost mechanism for advancing scientific credibility ahead of potential partnering discussions or further fundraising. Investors will be watching the ACCENT and AMPLICITY clinical datasets, particularly any updated overall survival figures, as the near-term value inflection points rather than the preclinical paper itself. Peer-reviewed publication in a journal of record would materially strengthen the evidentiary base.

Sector

Topic

Geography